wave test approv drive
increas volum diag sale growth
rais target price
rais estim significantli driven test
manag deliv solid beat vs expect consensu suspend
guidanc degre expect perhap signific takeaway
result manag commentari relat substanti increas
volum growth new test approv past week
expect come week view wave new test signific new
growth driver next year expect consensu estim
growth expect rise accordingli come month reiter outperform
rate increas price target
three diagnost test launch expect come week
launch three test past sever week includ lab-bas
serolog blood test two molecular test id point-of-car platform
lab-bas platform track deliv anoth lab-bas serolog test
later flow serolog test come week estim wave
test could reach annual volum mil molecular mil
serolog drive signific increment diagnost sale bil sale
ep respect continu growth
libr mitraclip remain growth driver libr grew mil
drive ww diabet growth management remain confid libr receiv
approv expect expand mitraclip reimburs fmr ultim grant
chang model rais sale ep
estim driven primarili higher diagnost sale
valuat target price base ebitda multipl
unchang estim ntm ebitda one-year forward bil previous
bil risk stabil epd em fx product delay greater expect impact
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
global manufactur provid diversifi
healthcar product medic devic equip area
endovascular structur heart
one-year valuat scenario base
ev/ebitda ntm ebitda one-year forward
ebitda bil
one-year valuat grey scenario base
ev/ebitda ntm ebitda one-year forward
ebitda bil
 close
addit detail takeaway
laboratori diagnost sale mil mil decreas driven lower
routin test volum due molecular diagnost sale mil
mil increas driven launch sever new test kit includ
compani real-time molecular test run abt real-time
system march ship mil test plan ramp capac ship mil per month
begin april addit also launch lab base serolog test test
detect igg antibodi see point diagnost sale
mil mil increas driven launch new rapid test platform id
patient compani ship mil test plan increas
capac mil june rapid diagnost sale mil in-lin increas
signific increas diagnost sale estim rais estim
abt diagnost busi bil bil driven primarili
three addit test expect approv serolog test architect/alin
lab platform later flow serolog test sold test
busi line first serolog test approv week expect ship
approxim mil test june project two test ship unit slightli
lower volum first although time could potenti meet exceed
level assum increment gross margin test theoret posit
impact ep next three year increas project
ep close match estim although assum rapid
build-out urgent deliveri test platform neg impact potenti lift
ep pleas see summari addit
assum month id test month architect later test
monthli includ april estim revisionid rapid molecular test ad april estim revisionarchitect serolog ep increas cse charl martineau pm univers toronto april
ww pediatr nutrit sale bil mil increas reflect posit
impact pandem perform led increas demand
late march ahead shelter-in-plac restrict relat ww adult nutrit
sale mil mil increas
sale key emerg market india brazil russia china increas organ
basi last quarter em sale decreas organ compar
increas growth establish pharma led sever
geographi russia brazil sever countri across latin america southeast asia
electrophysiolog sale mil mil decreas pressur declin
hospit procedur volum due heart failur sale mil
mil increas due less elect natur busi structur heart
sale mil decreas diabet sale mil
increas led on-going uptak freestyl libr report world-wide sale
mil organ quarter obtain reimburs coverag
freestyl libr japan peopl type diabet manag current await
libr approv overal sale growth cardiovascular neuromodul busi
neg impact reduc procedur volum due howev
anticip strong demand avail healthcar resourc return normal level
guidanc remov due amid impact
manag withdrew previous issu guidanc organ sale growth
ep due uncertainti regard durat impact covid-
 op margin bp cse
base analysi sale net cog partial off-set higher sg
neglig non-op impact deliv ep beat rel estim
estimate bpop bpnon-op bpnet chg y/i charl martineau pm univers toronto april
figur revenu summari varianc analysi
salesy/i chg cc cg org cg salesy/i chg cc cg org cg nutrit emer charl martineau pm univers toronto april
chang model
increas sale estim ep estim
account increas sale compani test also made
adjust top-lin project beyond increas sale estim
per year averag ep estim increas
figur chang model
compani mention price
matt miksic vik chopra certifi respect compani secur individu analyz view express
report accur reflect person view subject compani secur part
compens directli indirectli relat specif recommend view express report
